Anthony Girand Founder Profile: VoyagerMed, HedgeNova and ProductProof.ai

Building Across Sectors: The Founder Philosophy Behind VoyagerMed, HedgeNova, and ProductProof.ai

If there's a throughline in my career — across Wall Street trading desks, enterprise SaaS boardrooms, law school, and three founded companies — it's this: the most consequential opportunities in business are almost always found at the intersection of complexity and access. Complex systems create friction. Friction creates gatekeepers. Gatekeepers create inequity. And technology, deployed with precision and genuine domain knowledge, has the power to dismantle all three.

That belief isn't abstract philosophy for me. It's the operating thesis I've tested in healthcare, in quantitative finance, and now in regulatory compliance. Each company I've built reflects a different expression of the same conviction: that technology and networks can make high-stakes, opaque systems more navigable — for the individuals and organizations that have historically been locked out of them.

Here's how that plays out across three ventures.

VoyagerMed: Reimagining Global Healthcare Access

VoyagerMed was born out of a frustration I suspect many people feel but rarely articulate: the world's best physicians are clustered in a handful of cities, predominantly in the United States, and the global patient population that could benefit from their expertise has almost no practical pathway to reach them. Not because the physicians are unwilling — most are — but because the infrastructure connecting international patients to U.S.-based specialists simply didn't exist in any coherent, scalable form.

As founder and CEO, I set out to build that infrastructure. VoyagerMed was a healthcare access platform designed to connect patients around the world with leading U.S. physicians — creating a structured, trusted channel for second opinions, complex case consultations, and coordinated care planning across borders.

What made this genuinely hard wasn't the technology. It was the trust architecture. International patients navigating a serious diagnosis are not in a position to tolerate friction, confusion, or ambiguity. They need clinical credibility, language support, care coordination, and a seamless experience that meets them where they are. Building that required partnerships with academic medical centers, careful physician vetting, and a product that felt more like a concierge than a portal.

"Healthcare access isn't just a logistical problem. It's a trust problem. The technology is only as valuable as the credibility it carries."

The lessons I took from VoyagerMed were formative. I learned how to build in a regulated, high-stakes environment where the cost of error is measured in human wellbeing. I learned that partnerships matter more than features in markets where trust is the primary currency. And I learned that even the most well-intentioned platform will fail if it doesn't deeply understand the workflow and psychology of its end user — in this case, a patient who is frightened, far from home, and placing enormous trust in a system they've never used before.

HedgeNova: Democratizing Institutional-Grade Investment Intelligence

My background on Wall Street gave me a front-row seat to one of the most persistent structural inequities in financial markets: the gap between institutional investment infrastructure and what's available to everyone else. Hedge funds and asset managers have spent decades and billions of dollars building quantitative research capabilities, proprietary data pipelines, and algorithmic systems that generate a durable informational edge. Retail investors and smaller family offices, by contrast, are working with a fraction of that intelligence.

HedgeNova is my exploration of what happens when you apply modern AI — large language models, agentic research pipelines, and quantitative modeling — to close that gap. The thesis is straightforward: the same kind of systematic, data-driven investment research that institutional players have historically monopolized can now be constructed, at meaningful quality, using the AI infrastructure that has become accessible over the last several years.

This isn't a robo-advisor play. It's not about automating a brokerage account. HedgeNova is about building genuinely sophisticated analytical infrastructure — the kind that surfaces signal from noise across earnings calls, macro indicators, sector rotation patterns, and alternative data sources — and making that available to a broader class of investors.

What I've found in building HedgeNova is that the AI capability is real, but the differentiation lies in the domain expertise layered on top of it. Anyone can prompt a language model to summarize a 10-K. Very few people know how to architect a research system that synthesizes that summary against a relevant peer set, a historical base rate, and a current macro regime — and then surfaces an actionable insight rather than a data dump. That's the hard part. And it's where my years working across financial markets and enterprise AI systems become directly relevant.

ProductProof.ai: Agentic Compliance Infrastructure for the Regulated Economy

My current primary venture — and the one I'm most focused on building right now — is ProductProof.ai. This is where my legal background, my enterprise SaaS experience, and my AI work converge most directly.

The premise is this: the regulatory landscape facing product companies is accelerating in complexity faster than those companies can absorb. New frameworks, new enforcement regimes, new disclosure requirements — the compliance burden is increasing across industries, and the internal resources most companies have to manage it are not scaling proportionally. The result is a growing class of regulatory risk that is both underappreciated and deeply consequential.

ProductProof.ai is building agentic compliance infrastructure to address this. We're starting with MoCRA Intelligence — a purpose-built compliance platform for the cosmetics industry navigating the Modernization of Cosmetics Regulation Act. MoCRA represents the most significant federal overhaul of cosmetics regulation in over 85 years, and most companies in the space are either unaware of their exposure or scrambling to address it with manual processes and outside counsel fees that aren't sustainable at scale.

What we're building is not a static compliance checklist. It's an agentic system — meaning it actively monitors regulatory developments, maps them against a company's specific product portfolio, identifies gaps, and surfaces prioritized action items. Think of it as a compliance officer that runs continuously, never misses a Federal Register update, and doesn't bill by the hour.

• MoCRA Intelligence: Automated facility registration tracking, ingredient compliance monitoring, adverse event reporting readiness, and labeling requirement alignment — all mapped to a company's specific SKU portfolio.
• Agentic Architecture: The system doesn't just report on the regulatory environment — it reasons about it, identifies downstream implications, and flags risks before they become enforcement actions.
• Scalable for Regulated Industries: While we're starting in cosmetics, the architecture is designed to expand into adjacent regulated verticals — food, supplements, medical devices, and beyond.

The JD matters here. I'm not building a compliance tool from the outside looking in. I understand how regulatory text translates into operational obligation. I understand the difference between a guidance document and a binding rule. And I understand how enforcement agencies think — which means I understand what a defensible compliance posture actually looks like, versus what merely appears compliant on the surface.

The Common Architecture Across All Three

Looking across VoyagerMed, HedgeNova, and ProductProof.ai, the pattern is consistent. Each venture targets a domain where complexity is high, access has been limited, and the cost of navigating the system poorly is severe. In healthcare, that cost is clinical. In finance, it's economic. In regulatory compliance, it's legal and reputational.

In each case, the technology is not the product — it's the delivery mechanism. The actual product is navigability. It's the ability to move through a complex, high-stakes system with confidence, efficiency, and appropriate accountability.

That's what I've spent 30 years building toward. And with ProductProof.ai, I think we're finally building the version that gets closest to the core of the thesis.

The regulated economy is only getting more complex. The companies that build infrastructure to manage that complexity — rather than simply react to it — will have a durable advantage. That's the bet I'm making, and it's the kind of bet I've made before.